University of Greenwich speeds drug research with ThalesNano H-Cube

NewsGuard 100/100 Score

A collaboration between groups led by Dr. John Spencer at Greenwich University and Professor Simon Mackay and Professor Alan Harvey at Strathclyde University has led to the discovery of a novel class of benzodiazepines with submicromolar activity against trypanosoma brucei spp., a parasitic species that causes African trypanosomiasis or sleeping sickness in humans.

Dr. John Spencer, Reader in Medicinal Chemistry, said, "Rajendra Rathnam, one of my PhD students at Greenwich, has successfully synthesized a number of benzodiazepine containing amines by a variety of reduction methods from their nitro precursors including microwave reductions with Molybdenum hexacarbonyl/DBU or Tin (II) Chloride, but the H-Cube flow method provided compounds in approximately 5 minutes in high yields and without the need for work-up or column chromatography. Such an approach is very promising for the generation of libraries of bioactive molecules and can expedite drug discovery significantly."

The work was recently presented at the prestigious MedChem Europe 2009 Conference in Berlin (organized by Select Biosciences).

"We are proud that our technology can play an important role in advancing science," said Richard Jones, Director of Product Management at ThalesNano. "From its introduction, H-Cube has opened up vast new areas of chemistry due to its advantages of speed, selectivity and yield."

http://www.thalesnano.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diet's role in fighting vitiligo highlighted in new research